Investigational Drug Prevents Flu-induced Lung Injury
UH15-38 shows potential in preventing lung injury and reducing inflammation in severe influenza when administered even five days after infection.
Tag: antiviral
All
Latest
All
Latest
COPD Patients Open to Antiviral Nasal Spray to Reduce Seasonal Flare-Ups
A survey found individuals with COPD were overwhelmingly positive about the prospect of taking an antiviral nasal spray throughout the winter season to prevent COPD flare-ups.
All
Latest
HHS to Purchase 1.7M Supply of Molnupiravir Antiviral for COVID-19
The US government will procure approximately 1.7 million courses of an investigational COVID-19 antiviral molnupiravir (MK-4482) from Merck, pending EUA or approval from the FDA.
FDA to Fast-track Potential Coronavirus Antivirals
The US FDA will fast-track potential antiviral medications to treat coronavirus, President Donald Trump announced at a White House briefing Thursday.
Read More
Xofluza Expanded to High-risk Flu Patients
The US FDA has approved a supplemental New Drug Application for Xofluza to treat flu in patients 12 and older who are at high risk of developing flu-related complications.
Read More
Cidara Developing Investigational Flu Antiviral
Cidara Therapeutics has selected the antiviral conjugate (AVC) CB-012 as its first clinical development candidate from the company’s Cloudbreak influenza antiviral program.
Read More
Roche’s Xofluza Shows Benefits for High-risk Flu Patients
Roche’s investigational single-dose antiviral Xofluza showed superior efficacy in speeding up improvement of flu symptoms in people at high risk of complications.
Read MoreNew FDA-approved Antiviral to Fight the Flu
The FDA has approved single-dose antiviral Xofluza for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
Read More
FDA Fast Tracks RSV Antiviral BTA585
Biota Pharmaceuticals has been granted Fast Track designation from the FDA for its antiviral compound intended for the treatment of RSV.
Read MoreBiota Commences Dosing in Phase 2b Study of Rhinovirus Antiviral
Biota Pharmaceuticals Inc has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir for the treatment of human rhinovirus (HRV).
Read More